How investors reacted to Valeant’s $2.1B sell off: 4 key insights

After announcing plans to sell off four company assets, investors rallied behind Lovell, Canada-based Valeant Pharmaceuticals.

Advertisement

The company is attempting to lower its $30 billion in accrued debts.

Here is what you need to know.

1. Valeant shares closed Jan. 9, 2017 at $15.35 and opened the following day at $17.12 following the acquisition news.

2. The company ended its day at $16.42. As of 11 a.m. EST, Jan. 11, 2017, Valeant was trading at $16.26.

3. Valeant’s 52-week range is between $13 and $101.40.

4. The company has a market cap of $5.93 billion.

More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bradley Zins of the Billings Clinic
ASGE certifies Mercy Hospital: 3 things to know
Dr. Brian Davis hosts video on The Fundamentals of Endoscopic Surgery exam

Advertisement

Next Up in GI & Endoscopy

  • Gastroenterologists are raising concerns about the CMS’ finalized payment policies, according to a joint statement from the American College of…

  • As gastroenterology evolves, leaders are reimagining how to deliver comprehensive, patient-centered care.  Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland…

Advertisement

Comments are closed.